Next-Generation Regenerative Therapy for Wound Healing
Technology No. BRA08-01
Sorbitol Based Solution for Infant Constipation and Associated Pain
Technology No. SIN03-01
Palatable Bowel Preparation for Improved Colonoscopies
Technology No. POC01-03
Human Corneal Organoids for Treatment of Corneal Injury
Technology No. CHA10-03
Self-Assembling Protein Fibers and Hydrogels as Theranostic Agents
Technology No. MON02-15.19
Murine Cell Line - Kras G12D/p53 -/-
Technology No. WON02-10
Murine Cell Line - Kras G12D, Lkb1 -/-, p53 -/-
Technology No. WON02-09
Murine Cell Line - Kras G12D/Lkb1 -/-
Technology No. WON02-08
FINO2 Compound for Ferroptosis
Technology No. WOE01-04
Anti-human/mouse PrP antibody (TW1 clone) hybridoma cells
Technology No. WIS02-28
OT-II LAG-3-/- mouse
Technology No. WAN05-21
OT-I LAG-3-/- mouse
Technology No. WAN05-20
RAGE conditional knockout transgenic mice (Columbia)
Technology No. SCH08-11
AGER Conditional Knockout Transgenic Mice (Columbia)
Technology No. SCH08-10
Diaph1 conditional knockout transgenic mice (Columbia)
Technology No. SCH08-09
Addback clonal pair of Kras G12D/p53/Keap1 Murine Cell Line (HHMI/MIT)
Technology No. PAP02-10
Kras G12D/p53/Keap1 Murine Cell Line (HHMI/MIT)
Technology No. PAP02-09
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Brca1 -/-; MycOE
Technology No. NEE02-11
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Ccne1OE; MycOE
Technology No. NEE02-10
B6.Cg-Ptprca Cx3cr1tm1Litt/LittJ (Jax No. 008451) Transgenic mice (HHMI)
Technology No. LIT01-61
GHOST (3) CXCR4+CCR5+ cell line (NIH AIDS Reagent Program Catalog Number: 3942) (HHMI)
Technology No. LIT01-60
B6.129P2-Runx1tm1Tani/J transgenic mice (HHMI) (Jax No. 008772)
Technology No. LIT01-58
C57BL/6-Tg(Tcra,Tcrb)2Litt/J transgenic mice (HHMI) (Jax. No. 027230)
Technology No. LIT01-57
DC-SIGN transgenic mice (HHMI)
Technology No. LIT01-53
B6.FVB-Tg(Rorc-cre)1Litt/J transgenic mice (Jax. No 022791) (HHMI)
Technology No. LIT01-41
C57BL/6-Tg(Cd8a-cre)1ltan/J transgenic mice (Jax No. 008766) (HHMI)
Technology No. LIT01-38
Humanized mouse line expressing the human WT or CX3CR1I249/ M280 polymorphic variant (HHMI/USTA)
Technology No. LIT01-29
C.129P2-Cxcr6tm1Litt/J transgenic mice (HHMI) (Jax No. 005700)
Technology No. LIT01-10
B6.129P2-Cxcr4tm2Yzo/J transgenic mice (HHMI) (Jax No. 008767)
Technology No. LIT01-09
Plasmid SV-Ψ-MLV-env- (BEI catalog # 3422)
Technology No. LAN02-07
Pla2g12b floxed mice
Technology No. HUS02-17
ApoC3 KO mice
Technology No. HUS02-16
Leydig-cell specific MTP deficient mice
Technology No. HUS02-15
Placenta-specific MTP deficient mice
Technology No. HUS02-14
Zfp961 floxed mice
Technology No. HUS02-13
Casz1 floxed mice
Technology No. HUS02-12
Mouse Leydig MA10 cell line deficient in SREPB2 (ATCC parent)
Technology No. HUS02-11
Mouse Leydig MA10 cell line deficient in MTTP (ATCC parent)
Technology No. HUS02-10
Apolipoprotein B deficient hepatoma cell line (VA)
Technology No. HUS02-07
human hepatoma cell line deficient in microsomal triglyceride transfer protein (MTTP) (VA)
Technology No. HUS02-06
SERPINB2 deficient cell lines for enhanced AdV manufacturing purposes
Technology No. DIT01-03
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr X (not cloned)
Technology No. DAV06-26
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 13+21 (not cloned)
Technology No. DAV06-25
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 18 (not cloned)
Technology No. DAV06-24
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 12 (not cloned)
Technology No. DAV06-23
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 9 (not cloned)
Technology No. DAV06-22
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 8 (not cloned)
Technology No. DAV06-21
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 6 (not cloned)
Technology No. DAV06-20
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 7 gain (x2)
Technology No. DAV06-19
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-Chr 18q loss (x2)
Technology No. DAV06-17
Human Colonic Epithelial Cell (hCEC) Line (UTSW)-control Ctr sgNC (x2)
Technology No. DAV06-14
LS513 colorectal cancer (ATCC parent) - Chr 7-trisomic/7-disomic cell lines
Technology No. DAV06-06
LoVo Colorectal Cancer (ATCC parent) - Chr 5-trisomic/5-disomic cell lines
Technology No. DAV06-18
LoVo Colorectal Cancer (ATCC parent) - Chr 7-trisomic/7-disomic cell lines
Technology No. DAV06-05
Reh Cell line overexpressing NSD2 E1099K
Technology No. CAR01-04
UBA1 Knockout THP-1 Cell Line for the study of VEXAS (ATCC parent)
Technology No. BEC01-03
Axsl1 fl/fl:Tet2 fl/fl Conditional Knockout Mice
Technology No. AIF01-23
Susd6 fl/fl Conditional Knockout Mice
Technology No. AIF01-22
Clpb fl/fl Conditional Knockout Mice
Technology No. AIF01-21
C57BL/6 (Rosa-rtTA shTet3)
Technology No. AIF01-19
C57BL/6 (Rosa-rtTA shTet2)
Technology No. AIF01-18
C57BL/6 (Rosa-rtTA shTet1)
Technology No. AIF01-17
Conditional AsxL1 Knock-out Mouse Model (Jax No. 025665)
Technology No. AIF01-16
Next-Generation Trachea-Esophageal Organoids for Scalable Disease Modeling
Technology No. ROS09-02
First-in-Class Vaccine Platform to Halt Prion Transmission Across Species
Technology No. WIS02-20
Carbon-Coated Graphitic Carbon Nitride for Sodium-Ion Batteries
Technology No. TAY01-05
KaryoCreate: Generating Chromosome-Specific Aneuploidies in Human Cells
Technology No. DAV06-02
Targeting cooperative nutrient scavenging in cancer with pharmacological inhibition of CNDP2
Technology No. CAR06-02
Novel Immune Based Therapeutic Strategies to Target Tumors with Alterations in LKB1 Pathway
Technology No. PAP02-04
Non-Genetic Induction of Tumor Neoantigens via Translational Errors
Technology No. BAN03-02
Rapid Generation of Single-Chain Antibodies for Use as Chimeric Antigen Receptors (CARs)
Technology No. KOR01-08
iCADD: Next-generation Screening Platform for Identifying Small Molecular Glue Degraders
Technology No. PAG01-16
Targeting the Stress-Response Pathway to Promote Anti-tumor Responses
Technology No. PAP02-05
Novel Screening Platform to Identify Confirmation-Specific SHP2 Inhibitors
Technology No. NEE02-12
Tumor-Targeting Nanoparticles for Precision Chemotherapy in Cancer
Technology No. TRA02-06
Biomimetic Nanofibers Electrospun with Calreticulin as Wound Healing Agents
Technology No. GOL01-10
Usui Ryoho Reiki Manual Level 2
Technology No. SAL05-02
Inhibitory Peptides That Selectively Antagonize Neuropilin 1 (NRP1) for Precise Pain Treatment
Technology No. BUN01-02
Usui Ryoho Reiki Manual Level 1
Technology No. SAL05-01
Peptidomimetic Modulator of CaV2.2 N-type Calcium Channel for Treatment of Chronic Pain
Technology No. KHA03-01
GEMs: Genetically Encoded Multimeric Nanoparticles for Biophysical Analysis of Cells
Technology No. HOL03-01
In Silico, Machine Learning-Based Platform to Identify Disease-Causing Senescent Cells
Technology No. WOS01-01
Prognostic Tool for Risk Stratifying Patients with Epilepsy to Improve Clinical Outcomes
Technology No. SAX02-03
Simulated Microgravity Approach for Enhanced Stem Cell Potency
Technology No. TEO01-03
Omnivore RNA Pyrophosphatase: The Key to Universal 5′-end Deprotection
Technology No. BEL01-03
CX3CR-1GFP transgenic mice (B6.129P2(Cg)-Cx3cr1tm1Litt/J; Jax stock number: 005582)
Technology No. LIT01-37
Platform for Locally Assembling Antibody Drug Conjugates (ADCs) With Enhanced Specificity
Technology No. NEE02-08
Enhancing Neuronal Resistance to Neurodegeneration
Technology No. MAZ02-03
Mutant-Selective HER2 Antibodies for Treatment of Major Cancer Types
Technology No. KOI01-08
Genetically Engineered Mice for Heavy Chain Only Antibodies (HCAbs) Production
Technology No. KOR01-04
Diagnostic Interview for Seizure Classification Outside of Video EEG Recording (DISCOVER) Form
Technology No. FRE10-01
Intraoperative Ultra Rapid Digital Droplet PCR to Guide Tumor Resection
Technology No. EVR01-03
A Biomarker for Cerebral Amyloid Angiopathy (CAA) and Amyloid Related Imaging Abnormality Risk
Technology No. WIS02-27
Bright and Photostable Cyanine Dye Tags for Research Applications
Technology No. SAU02-01
Optimized Retron Editors for Enhanced Genome Engineering in Mammalian Cells
Technology No. POI01-07
Colonic Irrigation Solution
Technology No. POC01-01
Cysteine Depletion as a Treatment for Obesity and Associated Metabolic Disorders
Technology No. LIT01-56
Inherited Genomic Signature Testing for Improved Immune-Checkpoint Inhibition Cancer Therapies
Technology No. KIR03-03
Efficient Population Receptive Field Estimation with qPRF
Technology No. LU02-04
Hardware-Software Co-Design to Accelerate Garble Circuits
Technology No. REA01-02
Sindbis Virus-Based Vectors for the Oncolytic Immunotherapy of Solid Tumors
Technology No. MER02-24
Monoclonal Antibodies for Efficient Removal of Uremic Toxins in Chronic Kidney Disease Patients
Technology No. KON02-10
Repurposing Farnesyl Transferase Inhibitors for the Treatment of Cerebral Malaria
Technology No. ROD01-17
Targeting mutant NT5C2 in Acute Lymphoblastic Leukemia (ALL)
Technology No. CAR01-03
Apoptosis Inhibitor 5 (API5)-based Therapeutic for the Treatment of Inflammatory Bowel Diseases
Technology No. CAD01-05
Ultra High-Fidelity Single Molecule Sequencing
Technology No. EVR01-05
NYU CHIIMERAâ„¢: VIRTUAL MICROSCOPE
Technology No. TRI01-02
Polysubstance Use Assessment Tool (PAT)
Technology No. BUN02-01
A Novel Predictive Classifier of Follicular Lymphoma Patients for Improved Treatment Strategy
Technology No. PAR08-01
CARPOOL: A High Throughput Drug Screening Platform
Technology No. SUL02-02
S-allylcysteine for Use in the Prevention and Treatment of Plasma Cell Dyscrasias
Technology No. ORL01-32
Selective KRAS(G12D)-Binding Monobodies for the Treatment of Cancer
Technology No. KOI01-07
SCRATCH-seq: Capturing Dynamic Genetic Changes in Lymphocytes
Technology No. KOR01-06
Selective NRAS-Binding Monobodies for the Treatment of Cancer
Technology No. KOI01-10
Monodisperse PVT Spheres
Technology No. PVT SPHERES
Topical Inhibition of HIF-1a as a Novel Therapeutic Strategy for Inflammatory Skin Diseases
Technology No. NAI02-03
Catalysts to Efficiently Convert Lignin Biomass to Valuable and Sustainable Chemicals
Technology No. DIA01-01
Monodisperse PS Spheres
Technology No. PS Spheres
NYU adVANCE Software
Technology No. MOR04-01
Clinical Prognostic Models for Stage II Melanoma Using Tumor miRNA Signatures
Technology No. POL01-05
Multivalent Assembled Proteins (MAPs): Therapeutics for Cancer and Infectious Diseases
Technology No. MON02-11
Local Anesthesia VR
Technology No. VRLA
Transcription-Associated Cas9 Targeting in Eukaryotic Cells
Technology No. BOE01-20
Chip-based Prognostic Tool for Improved Leukemia Treatment Outcomes
Technology No. CHE11-02
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
Technology No. NEE02-05
Novel Probiotic Compositions for Improving Metabolism and Immunity
Technology No. BLA02-12
Therapeutic Hyaluronic Acid and Peptide Composition for Regenerative Repair of Cartilage Injury
Technology No. COW02-02
Injectable Therapeutic Hydrogel for the Treatment of Post-Traumatic Osteoarthritis
Technology No. LIU02-02, MON02-04
Hydrophobically Interspaced, Charged Peptides for the Treatment and Prevention of Dementia
Technology No. WIS02-26
Anti-CD97 Antibody-Drug Conjugates for the Treatment of AML and GBM
Technology No. KOI01-16
Biomarkers of Severe and Cerebral Malaria
Technology No. ROD01-18
Salt-Inducible Kinase Activators to Treat Bone and Mineral Diseases
Technology No. PAR07-01
High-Throughput Design and Engineering of Mammalian Cells
Technology No. TRO02-01
Ultrasonic Probe Device and System and Methods for Generating Ultrasonic Images
Technology No. TSU02-01
Device for the Treatment of Lower Extremity Deep Vein Thrombosis
Technology No. GAR05-01
ParentCorps Friends School
Technology No. BRO07-01
Small Molecule Inhibitors of SPNS2 for the Treatment of Chronic Inflammatory Diseases
Technology No. SCH14-01
Methods of Sensitizing Estrogen Receptor-Positive Breast Cancer to Endocrine Therapy
Technology No. SCH03-09
Genetic System to Selectively Generate Single-Sex Chickens
Technology No. DAV06-04
ParentCorps Parenting Program
Technology No. BRO07-01
ASRS DSM-5
Technology No. ADL01-06
Apolipoprotein B Peptide Mimics for Atherosclerosis Treatment
Technology No. GOL05-04
Efficient and High-Throughput Tool to Engineer Aligned 3D Collagen Matrices for Tissue Culture
Technology No. TEO01-01
Targeting Endocytosis in Nociceptors as a Non-Opioid Treatment Strategy for Chronic Pain
Technology No. BUN01-01
IL-17 Receptor Modulator Screen
Technology No. LIT01-52
Treatment of Melanoma Brain Metastasis by Inhibition of Amyloid Precursor Protein Cleavage
Technology No. HER02-07
Method of Treating Lung Cancer in Patients with LKB1 Genetically-Inactivated Tumors
Technology No. WON02-07
Vectored ACE2 Receptor Decoy for Prevention and Treatment of Pan-Coronavirus Infections
Technology No. LAN02-06
Nanobodies Targeting SARS-CoV-2 NSP9 for COVID Treatment
Technology No. PER03-04
Saliva-Based Cytokine Score to Predict the Severity of Clinical Periodontal Inflammation
Technology No. KAM01-01
![CD11c-DTR Transgenic Mice (B6.FVB-1700016L21RikTg [Itgax-DTR/EGFP] 57Lan/J; Jax stock number: 004509 )](https://storage.googleapis.com/elucid3-storage-1-us/uw/product/9154/2/cd11c-dtr-transgenic-mice-b6fvb-1700016l21riktg-itgax-dtregfp-57lanj-jax-stock-number-004509--01.jpg?mtime=20240110144423)
TET2 Conditional Knockout Transgenic Mice
Technology No. AIF01-14
CHIIMERAâ„¢ 3D Anatomy Education Software
Technology No. TRI01-01
iScore: A Novel Method for Improved Risk Stratification of AML Patients
Technology No. AIF01-12
Monodisperse PMMA Spheres
Technology No. PMMA SPHERES
Novel Targets for Cancer Therapy
Technology No. WON02-04
Identification of Zinc Fingers and Their DNA Targets
Technology No. NOY01-01
Novel Method for Labeling Cells and Living Animals with Isotopically Label Gases
Technology No. PAC02-01
Tau Kinase Inhibitor for Preventing or Treating Glucocorticoid-Induced Osteoporosis
Technology No. LIU02-10
Treatment for Alzheimer’s Disease by Inhibiting Formation of Platelet Micro-Clots
Technology No. WIS02-24
Antibody-Based Inhibitors of the Staphylococcus aureus Multidrug Efflux Pump NorA
Technology No. KOI01-06
Osteoarthritis (OA) Biomarker Suitable as a Point-of-Care Diagnostic
Technology No. WIS01-03
Methods of Treating Cancers Having a Deregulated Metabolic Pathway
Technology No. PAP02-01
A Novel Small Molecule PABA Derivative C45-NA Enhances Anti-Tumor Activity
Technology No. BRO02-03
Therapeutic Targeting of KMT2D Mutant Lung Cancer Via RTK-RAS Signaling Inhibition
Technology No. WON02-05
Targeting the SARS-CoV-2 Viral-Immune Interaction for COVID-19 Therapy
Technology No. WAN05-01
Viral Vector Expression of Gabrb1b for the Treatment of Perceptual Deficits
Technology No. SAN06-01
Novel miRNA and Protein Therapeutic Targets to Reduce Atherosclerosis
Technology No. HUS02-04
Targeting a Novel Metabolic Network for Pancreatic Ductal Adenocarcinoma (PDAC) Treatment
Technology No. KIM06-01
Paper-Based, Multiplexed Lamp Diagnostic for Pathogen Detection
Technology No. QAS01-09
Engineered Progranulin: A Promising Therapeutic Approach for Autoimmune Diseases
Technology No. LIU02-03
PHOTACS: Photo-Activatable PROTACS
Technology No. TRA03-01
Multivalent Steroid Conjugates for Treatment of Castration-Resistant Prostate Cancer (CRPC)
Technology No. KIR01-10
Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
Technology No. MOO02-06
FGF23 Ligand Trap: New Biologic for Treating Kidney Diseases
Technology No. MOH01-02
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
Technology No. MOH01-03
ASRS v1.1 18-Question Symptom Checklist
Technology No. ADL01-07
Adhesive Bandage for Rapid Pathogen Immune Response Detection
Technology No. QAS01-09
Angiotensin-Converting Enzyme 2 (ACE2) Immunoadhesin Microbody
Technology No. LAN02-03
Nano Zeolite-Y: A Novel and Cost-Effective Antibacterial Composition
Technology No. ANI01-01
Targeting RNA Viruses Using Inhibitors of METTL3
Technology No. MOH02-08
ASOs Targeting CHROMR for the Treatment of Inflammatory Diseases
Technology No. MOO02-07
Novel Enzyme in CoQ10 Biosynthesis Pathway as a Novel Target to Treat Neurological Diseases
Technology No. PAC02-02
PKP2cKO Transgenic Mouse Model
Technology No. DEL05-01
Anti-CD99 Antibodies Cytotoxic to Leukemia
Technology No. KOI01-05
Oral Insulin Delivery Nanoparticles for Diabetes Treatment
Technology No. TRA02-04
Photoactivatable Lipid Nanoparticles for Drug Delivery
Technology No. TRA03-04
TET2 Modulators for the Treatment of Cancer and Inflammatory Diseases
Technology No. AIF01-09
Novel Biomarkers for Detection and Treatment of Immune Deficiencies During Pregnancy
Technology No. HAN04-01
Smart Braces
Technology No. TEI01-04
Novel Wound Healing Hydrogels
Technology No. RAB02-02
Non-Antibiotic Treatment of Staphylococcal Infections
Technology No. NOV01-14
Endock: Docking Station for Medical Instruments
Technology No. MON04-01
Succinate Receptor 1 (SUCNR1) Antagonists to Treat Neuroinflammation
Technology No. LI06-03
Avobenzone-Dendrimer Conjugates
Technology No. WEC01-04
NSP14/10 Complex Inhibitors for the Treatment of SARS-CoV-2 and Pan-Coronavirus Infections
Technology No. PAG01-15
Video-Enabled, AI-Based Fire Detection
Technology No. PAN01-05
Novel MicroRNA-30c Analogs to Reduce Secretion of Apolipoprotein B in Human Hepatoma Cells
Technology No. HUS02-03
A Novel Blood Marker for Prognostication and Treatment of Non-Small Cell Lung Cancer
Technology No. PAS02-13
Transgenic Mouse Model Expressing C217G Uromodulin
Technology No. WU01-01
